![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
No Clinically Significant Interaction of MK-3682 With the HIV Medications Dolutegravir, Raltegravir, Rilpivirine, and Tenofovir Disoproxil Fumarate
|
|
|
Reported by Jules Levin
The 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy
Washington, DC
June 8-10, 2016
Wei Gao; Leticia Arrington; Xiaoli Shirley Glasgow; Julie Luk; Elizabeth G. Rhee; William L. Marshall; Nancy Kim*; Marian Iwamoto; and Eugene E. Marcantonio *Corresponding author
Merck & Co., Inc., Kenilworth, NJ, USA
![Clin1](../images/061716/061716-8/Clin1.gif)
![Clin2](../images/061716/061716-8/Clin2.gif)
![Clin3](../images/061716/061716-8/Clin3.gif)
![Clin4](../images/061716/061716-8/Clin4.gif)
![Clin5](../images/061716/061716-8/Clin5.gif)
![Clin6](../images/061716/061716-8/Clin6.gif)
![Clin7](../images/061716/061716-8/Clin7.gif)
![Clin8](../images/061716/061716-8/Clin8.gif)
![Clin9](../images/061716/061716-8/Clin9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|